Cannabinoid News and Research

Latest Cannabinoid News and Research

CB2 receptors might serve as potential therapeutic targets for cerebral ischemia

A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.

22 Feb 2013

Agilent launches new application compendiums on designer drug testing and toxicology of oral fluids

Agilent Technologies Inc. today introduced new application compendiums on designer drug testing and toxicology of oral fluids.

5 Feb 2013

Acetaminophen may improve postoperative outcomes

Prophylactically administered intravenous acetaminophen could reduce postoperative nausea and vomiting, research suggests.

16 Jan 2013

e-Therapeutics’ ETS2101 cancer trials on track

e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

18 Dec 2012

Synthetic marijuana linked to 11,406 of 4.9M drug-related ED visits in 2010

Street forms of synthetic cannabinoids - so-called "synthetic marijuana" - were linked to 11,406 of the 4.9 million drug-related emergency department (ED) visits in 2010, according to a new report by the Substance Abuse and Mental Health Services Administration (SAMHSA).

6 Dec 2012

‘Pain as reward’ raises tolerance threshold

An individual’s ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.

5 Dec 2012

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

Study identifies monoacylglycerol lipase as new therapeutic target to treat Alzheimer's

Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease.

2 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Link between marijuana use and cannabinoid hyperemesis

Marijuana use-both natural and synthetic-may cause cannabinoid hyperemesis (CH) a little-known but costly effect that researchers suggest is a serious burden to the health care system as it often leads to expensive diagnostic tests and ineffective treatments in an effort to find the cause of a patient's symptoms and provide relief, according to two separate case reports unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

23 Oct 2012

Cannabis and the endocannabinoid system: an interview with Dr Leonora Long

Cannabis has both physical and behavioural effects. People using cannabis can experience feelings of euphoria (well-being), hunger, sleepiness, problems with motor coordination, and sometimes feelings of anxiety and paranoia.

15 Oct 2012

Increasing marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X

American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

MDA7 compound shows promise against Alzheimer's disease

A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

3 Sep 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

New drug can aid in losing weight and keeping it off

A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

28 Jul 2012